CRA experts advised counsel and presented before the FTC on transactions involving Novartis’ acquisition of cancer drugs from GlaxoSmithKline, GSK’s joint venture with Novartis on consumer health, and Novartis’s sale of Novartis Animal Health to Eli Lilly & Co. The deals ultimately went forward with certain divestitures.
CRA Competition economists contribute to article-by-article commentary on the EU Foreign Subsidies Regulation
It gives the European Commission far-reaching powers to scrutinize financial contributions from non-EU governments to companies active in the EU, including in...